BMT CTN PROTOCOL 1507: Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease
MD Anderson Study Status
Hydroxyurea, Rabbit-ATG, Thiotepa, Fludarabine, Cyclophosphamide, Mesna
This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with severe SCD; and (2) adults with severe SCD.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Sickle Cell Disease
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.